6-溴-4,4-二甲基色满-2-酮 | 164012-31-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 3,4-二氢香豆素
• 中文名称: 6-溴-4,4-二甲基色满-2-酮
• 英文名称: 4,4-dimethyl-6-bromo-2-oxo-chroman
• 英文别名: 6-bromo-4,4-dimethylchroman-2-one；2H-1-Benzopyran-2-one, 6-bromo-3,4-dihydro-4,4-dimethyl-；6-bromo-4,4-dimethyl-3H-chromen-2-one
• CAS: 164012-31-1
• 化学式: C₁₁H₁₁BrO₂
• 分子量: 255.111
• InChiKey: ZMEGAKQYQYQIHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-溴-4,4-二甲基色满-2-酮 在 4-二甲氨基吡啶 、 四(三苯基膦)钯 、 palladium 10% on activated carbon 吡啶 、 氢氧化钾 、 氢气 、 三乙胺 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 20.0~100.0 ℃ 、101.33 kPa 条件下， 反应 29.17h， 生成 3-(2-(2,2-dimethylacetoxy)-5-(ethoxy(diethylphosphonomethyl)phosphinoyl)phenyl)-3-methylbutanoic acid
  参考文献：
  名称：

  Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections

  摘要：

  本发明涉及磷酸化氟喹诺酮及其抗菌类似物，以及使用这些化合物的方法。这些化合物可用作抗生素，用于预防和/或治疗骨骼和关节感染，特别是用于预防和/或治疗骨髓炎。

  公开号：

  US20080287396A1
• 作为产物：
  描述：

  3-methyl-but-2-enoic acid 4-bromo-phenyl ester 在 aluminum (III) chloride 作用下， 以 二氯甲烷 为溶剂， 以57%的产率得到6-溴-4,4-二甲基色满-2-酮
  参考文献：
  名称：

  Compounds having activity as inhibitors of cytochrome P450RAI

  摘要：

  具有通式1的化合物，其中符号的含义在说明书中定义，是细胞色素P450RAI（视黄酸诱导型）酶的抑制剂，并用于治疗对视黄酸治疗有反应的疾病。

  公开号：

  US06359135B1

文献信息

• [EN] METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B<br/>[FR] PROCEDES PERMETTANT DE TRAITER DES TROUBLES SENSIBLES AU RETINOIDE AU MOYEN D'INHIBITEURS SELECTIFS DE CYP26A ET DE CYP26B
  申请人：ALLERGAN INC

  公开号：WO2005058301A1

  公开（公告）日：2005-06-30

  The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.

  本发明提供了一种治疗患有视黄酸反应性障碍的个体的方法。在一个实施例中，一种方法包括向个体施用有效量的选择性CYP26B抑制剂，所述选择性CYP26B抑制剂相对于CYP26A至少具有10倍的选择性。在另一个实施例中，一种方法包括向个体施用有效量的选择性CYP26A抑制剂，所述选择性CYP26A抑制剂的化学公式如说明书所述。本发明还提供了用于识别选择性CYP26A抑制剂或选择性CYP26B抑制剂的筛选方法。
• Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
  申请人：Allergan Sales, Inc.

  公开号：US06313107B1

  公开（公告）日：2001-11-06

  Novel compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification, and certain previously known compounds have been discovered to act as inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. The compound can also be used in co-treatment with retinoids.

  具有1至8号式的新化合物，其中符号的含义在说明书中有定义，并且已发现某些先前已知的化合物可作为细胞色素P450RAI（诱导性维生素A酸）酶的抑制剂，并用于治疗对维生素A酸治疗产生响应的疾病。该化合物还可与维生素A酸一起进行联合治疗。
• Acetylenes disubstituted with a phenyl or heteroaryl group and a
  申请人：Allergan, Inc.

  公开号：US05399561A1

  公开（公告）日：1995-03-21

  Compounds of the formula ##STR1## where R.sub.1 and R.sub.2 are hydrogen, lower alkyl of 1-6 carbons, or halogen; R.sub.3 is hydrogen, lower alkyl of 1-6 carbons, halogen, OR.sub.11, SR.sub.11, OCOR.sub.11, SCOR.sub.11, NH.sub.2, NHR.sub.11, N(R.sub.11).sub.2, NHCOR.sub.11 or NR.sub.11 COR.sub.11 ; X is O, S or NR' where R' is hydrogen or lower alkyl of 1-6 carbons; Y is phenyl or a heteroaryl group selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl and oxazolyl; A is (CH.sub.2).sub.n where n is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds; B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR.sub.8, CONR.sub.9 R.sub.10, --CH.sub.2 OH, CH.sub.2 OR.sub.11, CH.sub.2 OCOR.sub.11, CHO, CH(OR.sub.12).sub.2, CHOR.sub.13 O, --COR.sub.7, CR.sub.7 (OR.sub. 12).sub.2, or CR.sub.7 OR.sub.13 O, where R.sub.7 is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R.sub.8 is an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or R.sub.8 is phenyl or lower alkylphenyl, R.sub.9 and R.sub.10 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl or lower alkylphenyl, R.sub.11 is lower alkyl, phenyl or lower alkylphenyl, R.sub.12 is lower alkyl, and R.sub.13 is divalent alkyl radical of 2-5 carbons, have retinoid-like biological activity.

  式为##STR1##的化合物，其中R.sub.1和R.sub.2是氢、1-6个碳的低烷基或卤素；R.sub.3是氢、1-6个碳的低烷基、卤素、OR.sub.11、SR.sub.11、OCOR.sub.11、SCOR.sub.11、NH.sub.2、NHR.sub.11、N(R.sub.11).sub.2、NHCOR.sub.11或NR.sub.11 COR.sub.11；X是O、S或NR'，其中R'是氢或1-6个碳的低烷基；Y是苯基或从吡啶基、噻吩基、呋喃基、吡嗪基、嘧啶基、吡咯基、噻唑基和噁唑基中选择的杂环基；A是(CH.sub.2).sub.n，其中n为0-5、3-6个碳的低支链烷基、3-6个碳的环烷基、2-6个碳和1或2个双键的烯基、2-6个碳和1或2个三键的炔基；B是氢、COOH或其药学上可接受的盐、COOR.sub.8、CONR.sub.9 R.sub.10、--CH.sub.2 OH、CH.sub.2 OR.sub.11、CH.sub.2 OCOR.sub.11、CHO、CH(OR.sub.12).sub.2、CHOR.sub.13 O、--COR.sub.7、CR.sub.7 (OR.sub.12).sub.2或CR.sub.7 OR.sub.13 O，其中R.sub.7是含有1-5个碳的烷基、环烷基或烯基，R.sub.8是1-10个碳的烷基或5-10个碳的环烷基，或R.sub.8是苯基或低烷基苯基，R.sub.9和R.sub.10独立地是氢、1-10个碳的烷基或5-10个碳的环烷基，或苯基或低烷基苯基，R.sub.11是低烷基、苯基或低烷基苯基，R.sub.12是低烷基，R.sub.13是2-5个碳的双价烷基基团，具有类视黄醇生物活性。
• Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
  申请人：Vasudevan Jayasree

  公开号：US20050176689A1

  公开（公告）日：2005-08-11

  Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.

  本说明书提供的1至17式化合物可以特异性地抑制细胞色素P450RAI-1酶或细胞色素P450RAI-2酶。
• Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B
  申请人：Vasudevan Jayasree

  公开号：US20050187298A1

  公开（公告）日：2005-08-25

  The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.

  本发明提供了治疗具有视黄醇响应性疾病的个体的方法。在一种实施方式中，该方法涉及向个体施用有效量的选择性CYP26B抑制剂，该选择性CYP26B抑制剂相对于CYP26A具有至少10倍的选择性。在另一种实施方式中，该方法涉及向个体施用有效量的选择性CYP26A抑制剂，该选择性CYP26A抑制剂具有在规范中列出的化学式。本发明还提供了筛选方法，用于识别选择性CYP26A抑制剂或选择性CYP26B抑制剂。